Clinical trial registry changes: May 2026

Among the trials TrialRedline tracks, 81 changed their ClinicalTrials.gov record in May 2026: 2 status changes to terminated, withdrawn or suspended, 20 primary outcome text edits, 27 completion dates moved later, 4 completion dates moved earlier, 30 enrollment changes, 39 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.

81Trials with a recorded change
83Registry updates
63Sponsors

Trials terminated, withdrawn or suspended

2 in May 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.

Primary outcome text edits

20 in May 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To explore the efficacy of Halneuron in the treatment of patients with Chemotherapy-Induced Neuropathic Pain Measure: To explore the Safety of Halneuron in the treatment of patients with Chemotherapy-Induced Neuropathic Pain. After: Measure: NRS Pain Measure: Safety Assessments.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Safety and tolerability of JADE101 in participants with IgA nephropathy. After: Measure: Incidence of treatment-emergent adverse events (safety and tolerability).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression free survival (PFS) per Investigator in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population. After: Measure: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) Measure: Overall survival (OS) in the RAS G12X-C population.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Radiographic Progression-free Survival (rPFS) By Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Criteria Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Maximum Plasma Concentration (Cmax) of FG-3246, Total Anticluster of Differentiation 46 Antibody (CD46), and Free Monomethyl Auristatin E (MMAE). After: Measure: Radiographic Progression-free Survival (rPFS) By Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Criteria Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Maximum Plasma Concentration (Cmax) of FG-3246, Total Anti-cluster of Differentiation 46 Antibody (CD46), and Free Monomethyl Auristatin E (MMAE).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) and LDL-C by Preparative Ultracentrifugation (LDL-C [PUC]) up to Week 24. After: Measure: Percent Change From Baseline in Fasting LDL-C at Week 24.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs). After: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment Emergent Adverse Events (TEAEs) during the study. After: Measure: Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis Measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis). After: Measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis Measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis) Measure: Incidence of Treatment Emergent Adverse Events.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To Measure the Protective Efficacy of Oral Administration of Travelan Compared to Placebo Against Moderate-to-severe Diarrhea Following With E.Coli (ETEC) Challenge.. After: Measure: Protective Efficacy of a Single Daily Dose of Travelan Against Moderate-to-severe Diarrhea Following Challenge With Enterotoxigenic E. Coli (ETEC) Strain H10407..

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002 Measure: Cohort A: Incidence of high-grade Complete Response at any time by subgroup (BCG naive and BCG exposed > 24 months) according to central pathology after treatment with TARA-002. After: Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in Eczema Area and Severity (EASI). After: Measure: Change in Investigator Global Assessment (IGA) at Week 8.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: To evaluate the feasibility of producing lifileucel using tumor samples obtained before (Cohort 3D) or during (Cohort 3E) frontline platinum doublet chemotherapy and pembrolizumab in patients with Stage IV NSCLC. After: Measure: Objective Response Rate Measure: Safety Profile Measured by Grade ≥3 TEAEs Measure: Percentage of patients for whom lifileucel is successfully manufactured and meets release specification.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Sternal Wound Infection (SWI) Rate. After: Measure: Proportion of Participants With a Sternal Wound Infection Event.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Assessment of Spondyloarthritis International Society (ASAS) criteria will be used to determine proportion of subjects achieving 40% Improvement (ASAS40 response). After: Measure: Percentage of participants achieving ASAS40..

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline in plasma tHcy levels. After: Measure: Change from baseline in plasma tHcy levels - Weeks 6 to 12.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: All-cause mortality (US FDA Only) Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only). After: Measure: All-cause Mortality Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Plasma pharmacokinetic (PK) profile of ARQ-151 cream 0.3% and its major N-oxide metabolite Measure: Incidence of adverse events Measure: Incidence of application site reactions. After: Measure: Plasma Concentration of Roflumilast Following Daily Application of Roflumilast Cream 0.3% Measure: Plasma Concentration of Major N-oxide Metabolite Following Daily Application of Roflumilast Cream 0.3% Measure: Number of Participants With an Adverse Event (AE) Measure: Number of Participants With Application Site Reactions.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (All-Comers).. After: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers). Measure: Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers)..

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of patients experiencing a best corrected visual acuity (BCVA) ≥15-letter loss from baseline through the primary timepoint as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at any two consecutive visits.. After: Measure: Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Phase 2: Assessment of novel Patient Reported Outcome instrument psychometric properties Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 3: Percentage of Participants Achieving Clinical Response. After: Measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response.

Check registry source

Completion dates moved later

27 in May 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.

Showing 25 of 27. Browse all tracked trials to open the rest.

Completion dates moved earlier

4 in May 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.

Enrollment changes

30 in May 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.

Showing 25 of 30. Browse all tracked trials to open the rest.

Other recruitment status changes

39 in May 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.

Showing 25 of 39. Browse all tracked trials to open the rest.

Cite this report

TrialRedline, “Clinical trial registry changes: May 2026”. https://trialredline.com/reports/2026-05

Based on public ClinicalTrials.gov record history. How we collect and check the data